Amgen Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Amgen Inc. (AMGN) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $8.22 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-13
- Amgen Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $8.22B, a 103.47% increase from fiscal 2024.
- Amgen Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $4.04B, a 0.17% decline from fiscal 2023.
- Amgen Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $4.05B, a 33.74% increase from fiscal 2022.
- Amgen Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $3.03B, a 63.57% increase from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $8.22B 10-K · filed 2026-02-13 |
| 2024-12-31 | $4.04B 10-K · filed 2026-02-13 |
| 2023-12-31 | $4.05B 10-K · filed 2026-02-13 |
| 2022-12-31 | $3.03B 10-K · filed 2025-02-14 |
| 2021-12-31 | $1.85B 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |